Resource impact statement
No significant resource impact is anticipated
NICE has recommended ozanimod as an option for treating moderately to severely active ulcerative colitis in adults, only if:
- conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or
- biological treatment cannot be tolerated or is not working well enough, and
- the company provides it according to the commercial arrangement (see section 2 of the guidance).
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option and the overall cost of treatment will be similar.
The previously published template for this patient group has been updated and replaced to include ozanimod and all other treatment options for moderately to severely active ulcerative colitis.
Organisations should complete both current and future uptake based on local practice in order to assess the financial impact.
The company has a commercial arrangement. This makes ozanimod available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount. The other treatment options have discounts that are commercial in confidence. For enquiries about Patient Access Scheme (PAS) discounts contact the company, alternatively there may be confidential discounts at local or national levels arranged through networks.
This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.
This page was last updated: